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Background: Doxorubicin (DOX) is widely used in both human and veterinary oncology although the onset of
multidrug resistance (MDR) in neoplastic cells often leads to chemotherapy failure. Better understanding of the
cellular mechanisms that circumvent chemotherapy efficacy is paramount. The aim of this study was to investigate
the response of two canine mammary tumour cell lines, CIPp from a primary tumour and CIPm, from its lymph
node metastasis, to exposure to EC50(20h) DOX at 12, 24 and 48 h of treatment. We assessed the uptake and
subcellular distribution of DOX, the expression and function of P-glycoprotein (P-gp) and Breast Cancer Resistance
Protein (BCRP), two important MDR mediators. To better understand this phenomenon the effects of DOX on the
cell cycle and Ki67 cell proliferation index and the expression of p53 and telomerase reverse transcriptase (TERT)
were also evaluated by immunocytochemistry (ICC).
Results: Both cell lines were able to uptake DOX within the nucleus at 3 h treatment while at 48 h DOX was absent
from the intracellular compartment (assessed by fluorescence microscope) in all the surviving cells. CIPm, originated
from the metastatic tumour, were more efficient in extruding P-gp substrates. By ICC and qRT-PCR an overall
increase in both P-gp and BCRP were observed at 48 h of EC50(20h) DOX treatment in both cell lines and were
associated with a striking increase in the percentage of p53 and TERT expressing cells by ICC. The cell proliferation
fraction was decreased at 48 h in both cell lines and cell cycle analysis showed a DOX-induced arrest in the S phase
for CIPp, while CIPm had an increase in cellular death without arrest. Both cells lines were therefore composed by a
fraction of cells sensible to DOX that underwent apoptosis/necrosis.
Conclusions: DOX administration results in interlinked modifications in the cellular population including a
substantial effect on the cell cycle, in particular arrest in the S phase for CIPp and the selection of a subpopulation
of neoplastic cells bearing MDR phenotype characterized by P-gp and BCRP expression, TERT activation, p53
accumulation and decrease in the proliferating fraction. Important information is given for understanding the
dynamic and mechanisms of the onset of drug resistance in a neoplastic cell population.
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The ability of cancer cells to circumvent the effect of
structurally unrelated chemotherapeutic agents is
defined as multidrug resistance (MDR) [1–4]. One of the
most efficient MDR mechanism is the overexpression of
ATP-binding cassette (ABC) transporters by neoplastic
cells that can remove substrates by pumping them out
of the cell. Modifications of the expression and activity
of ABC proteins can lead to an increased pumping out
of drugs from the intracellular compartment and there-
fore to a reduction of the effective concentration of the
drug in cancer cells [5, 6]. In human medicine, P-
glycoprotein (P-gp), encoded by the ABCB1 (or MDR-1)
gene and the Breast Cancer Resistance Protein (BCRP),
encoded by the ABCG2 gene, are two of the many ABC
transporters often associated with the MDR phenotype
[1, 7]. P-gp and BCRP efflux pumps are often co-expressed
on the lipid bilayer of cellular plasma membrane but can
also be found at the membranes of intracellular organelles
where drugs can be segregated [8–11].
One of the most used antineoplastic agents in both
human and veterinary medicine is the anthracycline
Doxorubicin (DOX). DOX exerts its effects by multiple
mechanisms including the production of free radicals,
intercalation into DNA strands and inhibition of topoi-
somerases I and II, causing damage to DNA, resulting in
the activation of caspases, which ultimately leads to
apoptosis [12, 13]. Nevertheless, DOX is a substrate of
both P-gp and BCRP, which can decrease its intracellular
concentration therefore limiting antineoplastic action
[14, 15]. Despite extensive clinical utilization, the mecha-
nisms of action of DOX remain under intense debate
and further understanding of DOX influence on cell bio-
logical events could lead to an improvement in the
drug’s efficacy [12, 13, 16]. Nowadays, cancer cell lines
are successfully used in many studies as an in vitro
model to study cancer biology, molecular pathways and
test the efficacy of anticancer drugs [17].
Mammary neoplasms are among the most common
tumours in dogs and humans [18]. In recent decades, ca-
nine mammary tumours (CMTs) have been successfully
used as a spontaneous model for breast cancer research
and important progress has been observed in veterinary
oncology concerning the treatment and knowledge of
this disease [19–21].
P-gp and BCRP expression in CMTs has been demon-
strated using techniques able to detect their presence at
the subcellular level [22–27], however studies investigating
the functionality of the pumps with regard to the chemo-
therapeutic exposure are still incipient in the dog [28–30].
The aims of the present study were: (1) to investigate
the MDR mechanism associated with DOX treatment on
two CMTs cell lines, comparing the expression of P-gp,
BCRP, tumour protein p53 (p53), the catalytic subunit oftelomerase, telomerase reverse transcriptase (TERT) and
the proliferation index Ki67 between standard condition
and exposure to DOX treatment, and (2) to establish a
repeatable in vitro model that allows to evaluate the
in vivo chemotherapeutic drugs effects.
Results
Cell viability and Doxorubicin hydrochloride treatment
Population doubling times (DT) were very similar in the
two cell lines: 23 h and 17 min and 20 h and 29min in
CIPp and CIPm, respectively. The effect of DOX treat-
ment on CIPp and CIPm viability was evaluated using
the MTT assay. The cell lines had very similar sensitivity
to DOX. The EC50 values at 20 h [EC50(20h)] were
12.08 μM and 9.431 μM for CIPp and CIPm, respect-
ively. The cell viability values, compared to the various
concentrations of chemotherapy treatment, are shown in
Fig. 1.
Doxorubicin-associated fluorescence evaluation
By fluorescence microscopy we observed the blue fluor-
escence of Hoecst33342 in all nuclei of both cell lines, as
well as a bright red fluorescence of DOX in the treated
cells. In both CIPp and CIPm, after 3 h of treatment, al-
most all cells have internalized DOX and are therefore
intensely colored red as shown in Figs. 2 and 3, respect-
ively. The superimposition of the images highlights how
the drug concentrates in the nucleus (Figs. 2f and 3f). At
48 h, all these surviving cells were unstained because
they have extruded DOX (Figs. 2i and 3i).
Cell cycle analysis by flow cytometry
We investigated the effect of DOX EC50(20h) at 3, 6, 12
and 20 h on CIPp and CIPm distribution in the cell cycle
phases.
CIPp, treated with EC50(20h) DOX showed a gradual
increase of cells in the S (DNA synthesis) phase com-
pared to the CTR (Fig. 4 and Additional file 1). Increase
in S phase was associated with a progressive decrease of
cells in G2/M (mitosis) phase and, at 20 h, there were no
cells in G2/M (Fig. 4). The cell cycle underwent there-
fore an arrest at the S phase because of DOX treatment.
Besides, the hypodiploid sub G0/G1-peak constantly in-
creased reaching 21.76% ± 5.42% at 20 h in treated CIPp
compared to 5.92% ± 2.61% in CTR cells (Fig. 4). Sub-
G0/G1 peak was composed by apoptotic cells and by
cells that had already lost their DNA by shedding apop-
totic bodies, cellular fragments containing pieces of
chromatin, broken nuclei, chromosomes and cellular
debris [31].
CIPm did not show any severe increase in the S phase
at any time point compared to the untreated controls.
However, similarly to CIPp, also CIPm as well presented
a gradual increase of the hypodiploid peak in DOX
Fig. 1 Effect of DOX on CIPp and CIPm cell viability. DOX impairs cell viability of canine mammary carcinoma cell lines, CIPp (dotted line) and CIPm
(continuous line). Cells were treated with increasing concentrations of DOX for 20 h. The values for EC50(20h) were normalized to the control cell lines
(untreated) evaluated in the same culturing conditions. Dose-response curves represent mean ± s.e.m. from three independent experiments, each
performed in quadruplicate. EC50(20h) values were calculated using nonlinear regression curve by Prism 7 software (GraphPad San Diego, CA, USA)
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3.52 ± 1.68%) (Fig. 4 and Additional file 2).
P-gp and BCRP gene expression after treatments with
Doxorubicin
CIPp and CIPm were treated with the EC50(20h) dose of
DOX and the P-gp and BCRP gene expression profiles
were measured by quantitative Real Time PCR (qRT-
PCR) at different treatment times (3, 6, 12, 20, 48 h).Fig. 2 Doxorubicin-associated fluorescence in CIPp. DOX in CIPp control ce
stained with Hoechst33342 in blue (a, d and g). DOX red fluorescence in b
fluorescence of the nuclei and the red fluorescence of DOXBCRP and P-gp were detectable in all samples. A signifi-
cant increase of both P-gp and BCRP mRNA expression
level is evident at 48 h treatment time point for both
CIPp (p = 0.0009 and p = 0.0132, respectively) and CIPm
(p = 0.0013 and p = 0.0209, respectively) vs controls
(Fig. 5). In addition, in CIPp at 12 h BCRP expression
was significantly higher in the DOX treated and at 3 h P-
gp expression of CIPm was significantly higher in the
DOX treated cells vs controls.lls (CTR) and after 3 h and 48 h of EC50(20h) treatment. Nuclei were
, e and h. The merge images (c, f and i) containing the blue
Fig. 3 Doxorubicin-associated fluorescence in CIPm. DOX in CIPm control cells (CTR) and after 3 h and 48 h of EC50(20h) treatment. Nuclei were
stained with Hoechst33342 in blue (a, d and g). DOX red fluorescence in (b, e and h). The merge images (c, f and i) containing the blue
fluorescence of the nuclei and the red fluorescence of DOX
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Western Blot analysis was performed to investigate
anti-P-gp (clone C494) and anti-BCRP (clone BXP-
21) antibodies specificity for dog antigens. Dog liver
tissue expressed a single band specific for P-gp and
BCRP at the expected molecular weight of 140 kDa
and 70 kDa, respectively (see Additional file 3). Anti-
p53, -TERT and -ki67 (Mib1) antibodies specificity
for dog tissues had been assessed in previous studies
[32–35].Fig. 4 Dean-Jett-Fox Univariate cell cycle analysis by Flow Cytometry. Fluor
Analyzer10 and analyzed by Flowlogic software (Miltenyi Biotec, Bergisch G
experiment was repeated three times. Representative DNA content frequen
and in CTR CIPp and CIPm at the same time pointImmunocytochemistry on chamber slides treated with
Doxorubicin hydrochloride versus untreated
P-gp, BCRP, p53, TERT expression and the Ki67 prolifera-
tion index were evaluated in CIPp and CIPm by immuno-
cytochemistry (ICC) at 12, 24, 48 h of treatment with the
EC50(20h) dose of DOX and compared to the correspond-
ing control cultures. Extremely high density of cells was
present at 48 h culture for the untreated culture; for the
48 h treatment group, in which cells were less numerous
due to the longer treatment exposure, all cells present inescence of the PI-stained cells was measured using MACSQuant®
ladbach, Germany). 2 × 105 cells were examined for each sample and
cy histograms in CIPp and CIPm treated for 20 h with DOX EC50(20h)
Fig. 5 P-gp and BCRP gene expression in CIPp and CIPm treated with DOX EC50(20h). Gene expression is calculated with the formula of 2
–ΔΔCt and
shows the fold of change of treated cells vs their relative controls. The bars represent the minimum and maximum expression range of the genes.
Asterisk indicates statistically significant differences (p < 0.05) calculated with the Student’s t test (comparing treated vs ctr at the same time points)
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comparisons are reported in Additional file 4.
Positive staining for P-gp and BCRP was localized at
the cell membrane segments, frequently on cytoplasmic
vacuoles membranes and less intensely as dispersed
granular staining in the cytoplasm (Fig. 6). The percentage
of P-gp positive cells were increased at all time points in
CIPp with a statistically significant increase at 24 and 48 h
of treatment (p < 0.0001). CIPm showed a significantly
increased percentage of P-gp positive cells at 48 h
(p < 0.0001) and a mild increase at 24 h treatment. A
significant increase in the percentage of BCRP positive
cells was seen at all treatment time points for CIPp
(p < 0.0001 at 12 and 24 h; p = 0.0151 at 48 h) and at
24 h and 48 h treatment for CIPm (p = 0.0103 and
p = 0.0413, respectively) compared to the controls. The
treatment with DOX was overall associated with an in-
crease in the percentage of P-gp and BCRP positive cells
in the culture by ICC (Fig. 6b and d). The fraction of cells
replicating in the populations was evaluated by the Ki67proliferation antigen as specific nuclear staining in Ki67-
positive cells (Fig. 6e and f). At 12 h both cell lines re-
vealed a significantly higher proliferative activity in the
DOX treated cultures compared to untreated controls.
At 24 h CIPm showed a mild decrease of the prolifer-
ation index, while CIPp proliferation index was sig-
nificantly increased compared to the respective
untreated controls (p = 0.0034). At 48 h of treatment a
decrease in the cellular proliferative fraction was present
for both cell lines, but statistically significative only
for CIPp (p = 0.0118).
P53-positive cell showed specific nuclear staining,
while cellular TERT-positivity was represented by nu-
clear and/or granular cytoplasmic staining (Fig. 6g–j).
A striking significant increase was observed for both
p53 and TERT expression, compared to controls at
each time points (p < 0.0001 at each time point)
except for CIPm at 48 h treatment when a higher per-
centage of TERT positive cells was detected in un-
treated cells.
Fig. 6 (See legend on next page.)
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Fig. 6 Immunocytochemistry on chamber slides treated with Doxorubicin. Untreated (a, c, e, g, i) and DOX-treated (b, d, f, h, j) CIPp and CIPm
ICC with graphs representing the % differences (Δ) in positivity between the controls and the DOX-treated cells for each antibody. Cell
percentages were averaged over triplicate samples, and the data are expressed as the mean ± SD, asterisk represent a significant difference (p <
0.05) between controls and treated cells by two-tail Fisher exact test. ICC at 24 h treatment for P-gp in untreated (a) and DOX-treated (b) CIPp cell
line. ICC for BCRP in untreated (c) and DOX-treated (d) CIPp cell line. ICC for Ki67 in untreated (e) and DOX-treated (f) CIPm cell line. ICC for TERT
in untreated (g) and DOX-treated (h) CIPp cell line. ICC for p53 in untreated (i) and DOX-treated (j) CIPp cell line; multinucleated cells, indicated
by the black arrow, are shown in (d) and (j) and cells with micronuclei, indicated by black arrowhead, are shown in (j). Figures at 200x
magnification
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increase in cell size for both cell lines and, for CIPp only,
the presence of multinucleated cells, often in association
with karyomegaly and multiple micronuclei (Fig. 6(d),
(h) and (j)).
MDR direct dye efflux assay
The MDR Direct Dye Efflux Assay was performed to
evaluate the functionality of P-gp and BCRP expressed by
CIPp and CIPm. In both CIPp and CIPm the fluorophore
efflux was evident at each time point becoming almost
complete at 24 h (Fig. 7). Vinblastine, a well-known sub-
strate for P-gp pumps, exerts a selective competitive in-
hibitory effect and was used as an internal control. In both
CIPp and CIPm, P-gp efflux capacity was dampened by
the treatment with Vinblastine at all time points; CIPm
were less affected by Vinblastine treatment as evidenced
by the difference (Δ) in MFI between positive control cells
and Vinblastine treated ones (P-V), CIPm were able to ex-
trude a larger dye quantity than the CIPp in any caseFig. 7 Multidrug Resistance Direct Dye Efflux Activity in CIPp and CIPm. Ce
presence or absence of Vinblastine for 15 min, 1, 4 and 24 h. After washing
were excluded from analysis. Cells incubated at 4 °C (negative control - N)
temperatures and the cells retain the dye. Cells incubated at 37 °C (positive
gp and BCRP are active and cells efflux the dye. Cells incubated at 37 °C in
higher fluorescence compared to control cells, as Vinblastine competes witexcept at 1 h (Fig. 7). Representative histograms of the
MDR Direct Dye Efflux Activity in CIPp and CIPm are
displayed in Fig. 7, where a peak shoulder is observed at
24 h in Vinblastine treated CIPp cells; this peak may be re-
lated to the presence of two cell populations, a smaller
one rich in channels, able to efflux a quantity of dye simi-
lar to positive control cells even in presence of the inhibi-
tory competitor, and a larger cell population in which the
efflux is clearly limited by Vinblastine presence (Table 1).Discussion
P-gp and BCRP changes at gene expression and cellular
phenotype levels after exposure to Doxorubicin
The administration of DOX significantly enhanced the
transcription of P-gp and BCRP genes, presumably asso-
ciated to a functional need of efflux pumps in cells tar-
geted by DOX [28, 36]. CIPp, the cell line established
from the primary CMT, at 48 h showed increase in the
gene expression of both P-gp and BCRP. CIPm, cellslls were loaded with DiOC2(3) and incubated at 4 °C, or at 37 °C in the
and PI staining, cells were analyzed by flow cytometry and dead cells
exhibit high fluorescence, as P-gp and BCRP are inactive at low
control - P) have a progressively lower fluorescence over time, as P-
the presence of Vinblastine (V) that specifically effluxes via P-gp, have
h the dye for efflux by P-gp
Table 1 Multidrug Resistance Direct Dye Efflux Activity in CIPp and CIPm
CIPp CIPm
Δ (N-P) MFI Δ (P-V) MFI Δ (N-P) MFI Δ (P-V) MFI
15min 43.87 ± 5.74 −33.34 ± 5.68* 41.55 ± 5.69 − 14.49 ± 5.38*
1 h 60.15 ± 5.81 −34.09 ± 5.33 59.75 ± 6.15 −29.15 ± 6.11
4 h 81.32 ± 5.25 −28.25 ± 6.01* 86.71 ± 5.13 −9.70 ± 5.08*
24 h 101.06 ± 4.98 − 13.58 ± 5.12* 101.47 ± 4.85 −3.49 ± 2.54*
Differences (Δ) between median fluorescence intensity (MFI) values: ΔN-P (negative controls at 4 °C - positive controls at 37 °C) represents the amount of
fluorescent dye effluxed at each time point, ΔP-V (positive controls at 37 °C - cells treated with Vinblastine at 37 °C) represents the reduction of dye effluxed in
presence of Vinblastine in CIPp and CIPm. Asterisk indicates a significative difference between the two cell lines in the same condition (Student’s t test p < 0.05)
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increase of BCRP than P-gp, compared to controls.
At ICC, the percentage of cells immunolabeled by P-
gp and BCRP was highly variable. CIPp manifested an
increase in the expression of both the transporters com-
pared to the controls at any time points, whereas in
CIPm the percentage of P-gp and BCRP positive cells
was higher at 24 h for BCRP and, at 48 h of treatment,
for P-gp. The difference in the results between ICC and
qRT-PCR can be explained by the fact that at early treat-
ment time points (12 and 24 h) DOX-sensitive cells died
while the cells bearing intrinsic DOX resistance remained
viable and could be stained by ICC. Instead, qRT-PCR
was able to detect an increase in the mRNA transcript
mostly evident at 48 h when cells subjected to treatment
enhance their transcription machine in order to increase
their ability to survive DOX treatment. Moreover, qRT-
PCR is a quantitative method that detects the presence of
a specific mRNA over the total mRNA in a cellular popu-
lation, but it does not allow the detection of cellular diver-
sity in the population; on the other hand ICC highlights
single positive cells but not to permit the quantifications
of the number of the pumps present in a single cells. The
number of P-gp and BCRP positive cells by ICC, is not ne-
cessarily related to the amount of gene expression de-
tected by qRT-PCR. The number of cells evaluated by
ICC in the chamber slides at 48 h was extremely reduced
by the EC50(20h) DOX treatment, hence representing a
bias for quantification of the pumps.
Intrinsic expression of P-gp and BCRP was shown in
the two cell lines examined in this study. The treatment
with DOX demonstrated that cells that were able to sur-
vive had a higher expression of both P-gp and BCRP
thus they escaped the drug action through MDR related
mechanisms [5, 37].
Drug resistance to vinblastine in CMTs cell lines is
documented [30] and a high expression of P-gp [29] and
BCRP [28] in CMT cell lines led to the conclusion that
the use of DOX could lead to chemoresistance in treated
bitches [28].
In the present study ICC has been a valuable technique
for assessing the subcellular localization of P-gp and BCRP
which were identified both at the plasma membrane andin the cytoplasm of the cells, lining cytoplasmic vacuoles.
The expression of both ABC-transporters has been docu-
mented at membranous level, where they exert their func-
tion of efflux pumps, extruding drug from the nucleus and
cytoplasm [5, 38, 39], while in the cytoplasmic cellular
compartment where they are found on cytoplasmic lyso-
somal vacuoles, known as drug safe houses, which have
the function of segregating the drug preventing its action
into the nucleus [10, 11, 40–42].
Another interesting finding at ICC was the presence of
a substantial fraction of cells showing karyomegaly,
micronuclei and multinucleated cells in treated CIPp
especially. This finding can be associated with a DNA
damage due to DOX treatment that increases ploidy and
severe nuclear anomalies of cancer cells including giant
cells, polyploid and polymorphism, comprising multinu-
cleated cells and micronuclei that have been reported as
an indicator of genetic instability [43–46].
Effects of Doxorubicin on cell cycle progression and
cellular proliferation – Ki67 index, p53 and TERT
In the present study DOX exposure showed an important
effect on both CIPp and CIPm affecting cellular
distribution in the cell cycle phases. The cytotoxic action of
DOX resulted in cell cycle arrest in S phase for CIPp com-
plemented by cellular death increase. On the contrary,
CIPm did not arrest at cellular checkpoints, but the reduc-
tion of cellular percentage in G0/G1 went on parallel with
cellular death increase. The absence of the arrest at S phase
in CIPm could be interpreted as a loss of the cellular check-
points associated with the progression of the tumour from
primary (CIPp) to metastatic (CIPm). Besides, changes in
Ki67 labeling index measured during treatment are report-
edly to be a superior predictor of response than similar
measurements taken prior to treatment [47]. DOX is
known for influencing the cell cycle and proliferative activ-
ity with different effect associated to the cell type and dose
of DOX itself [48] and can influence the proliferative activ-
ity in an heterogeneous way depending on the dose and the
cell line as well by different gene expression [49].
The most evident effects of DOX treatment on the
cellular phenotype were the striking increase in the
percentage of p53 and TERT positive cells for both cell
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points. In fact, DOX has multiple mechanism of ac-
tion involving, in some cases, the activation of p53
[48]. Moreover, the genetic instability, which is the
consequence of DOX administration and loss of wild
type p53 function, has been suggested as the property
which allows highly malignant cells to amplify the
MDR-1 gene and thus become resistant to a wide
spectrum of cytotoxic drugs [50].
Hence, an important information was that in both un-
treated cell lines p53 is functional/not mutated and that
DOX treatment could activate its function. P53 activa-
tion conceivably mediated the cell cycle arrest in the S
phase in CIPp and cellular death in CIPm. A functional
p53 can represent a protective mechanism in a neoplas-
tic population treated by DOX, in fact the arrest of the
cell cycle can lead to p53-mediated activation of repara-
tive processes in neoplastic cells that could therefore
survive the treatment and be able to regrow upon
chemotherapy withdrawal [49, 51, 52]. P53 function has
an important role in chemotherapy efficacy, mediating
apoptosis of neoplastic cells targeted by many drugs
[53–57].
At 48 h treatment an increase of the percentage of p53
positive cells is seen in untreated cell lines, probably be-
cause of hyper-confluence and deficiency of nutrients of
the cell culture [58].
A significant increase in TERT activation and expression,
both in nuclei and cytoplasm, is another finding in DOX
treated cell lines. These can be explained by an attempt of
neoplastic cells to protect themselves from the damage in-
duced by DOX, conferring drug resistance. Telomerase is
the ribonucleoprotein responsible for de novo synthesis and
maintenance of telomeres, and its activity is predominantly
observed in cancer cells [59, 60]. It is well known that a de-
creased expression or inhibited activity of telomerase in
cancer cells is accompanied by an increased sensitivity to
some drugs (e.g., DOX, cisplatin, or 5-fluorouracil) [55],
however, the mechanism of the resistance resulting from
telomerase alteration remains elusive [59]. Telomerase can
translocate from the nucleus into the mitochondria to pro-
tect the cells from apoptosis mediated by ROS stress, being
ROS production a well-known mechanism of damage from
DOX to neoplastic cells [59, 60]. TERT can prevent cell
death by elongating and rebuilding the telomeres and by
increasing TERT concentration in the mitochondria
preventing apoptosis, influencing therefore the efficacy of
the treatment [54, 59, 61, 62]. The minimal set of changes
necessary to obtain tumorigenic drug-resistant cells was
found to be expression of telomerase and inactivation of
p53 and pRb [63], thus as the pathways inactivated or acti-
vated in malignant neoplasms can also confer the ability to
acquire drug resistance as was observed also in our popula-
tions of cells.Internalization and extrusion of Doxorubicin at different
timepoints
The exact mechanism of action of DOX is complex and still
unclear. To exert its function, a drug must reach its intra-
cellular target that, in the case of DOX, is primarily the nu-
cleus [13, 15, 64]. After 3 h of treatment, DOX reached its
target in both CIPp and CIPm while at 48 h treatment the
drug was extruded from the few surviving cells. The Multi-
drug Resistance Direct Dye Efflux Assay showed that P-gp
and BCRP channels were active in both cell lines and able
to extrude the substrate in 24 h. Overall, CIPm were more
efficient at extruding the exogenous compound compared
to CIPp. Being CIPm derived from metastatic tumour this
finding could be associated to an increased drug resistance
capacity of the metastatic cells compared to their primary
counterpart, a phenomenon already reported both in vivo
and in vitro [65–68]. Since metastasis is the major cause of
cancer death, it is important to address the effect of chemo-
therapy on metastasis by accurately establish the response
of a cell population to the drug to be administered to en-
sure that the desired effect will be observed both in the me-
tastases and primary tumours [44, 48, 68]. Chemotherapy
can radically increase the speed of clonal evolution and lead
to new malignant and resistant clones that can cause
tumour metastasis. Several aspects of metastatic clones are
distinct from primary tumour formation and could influ-
ence drug development [69, 70].
The qRT-PCR and ICC positively correlate with the test
evaluating the transporters functionality (i.e. direct fluor-
escence of DOX). In fact, at 48 h the cells that survived
treatment showed a complete extrusion of DOX, therefore
carrying a phenotype particularly rich in P-gp and BCRP
canals. The Multidrug Resistance Direct Dye Efflux Assay
showed similar functionality of P-gp and BCRP in CIPp
and CIPm in basal conditions, while CIPm showed a de-
creased sensitivity to the competitive inhibition of the P-
gp canals by Vinblastine. CIPm, derived from the meta-
static carcinoma, has more efficient P-gp canals, or canals
of other types (i.e. MRP-1, LRP) compared to the primary
tumour. Moreower, the extrusion assay detected a more
complex response in CIPp, with the evidence of different
sub-populations of neoplastic cells. A fraction of cells in
the primary tumour were more effective in extruding Vin-
blastine and probably constitute the highly efficient popu-
lation of CIPm, in the metastatic tumour [68, 71, 72].
Severe effect on cell viability were seen at 48 h DOX
treatment, causing fewer cells available for examination,
therefore the results related to this time point should be
interpreted with caution.
Conclusions
The present study investigated the relationship between
cancer cells chemosensitivity, the neoplastic phenotype
and the subcellular distribution of the chemotherapeutic
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primary mammary tumour, and CIPm, initiated from the
corresponding lymph node metastases. These cell lines
were a valuable model to study the effect of chemotherapy
treatments and to investigate the mechanisms associated
with cell-survival and death in a subpopulation of cells
subjected to chemotherapy. Changes in the cell cycle, p53
expression and TERT activation are interlinked with the
modulation of P-gp and BCRP drug transporters and are
associated to drug resistance. These findings provide valu-
able information for revealing the correlation between
chemoresistance, phenotypic changes and proliferation
dynamics in the neoplastic populations that might signifi-




The canine mammary carcinoma cell lines, CIPp and CIPm,
were kindly provided by prof. Takayuki Nakagawa from the
University of Veterinary Medicine of Tokyo, Japan [73]. They
were both obtained from a tubular carcinoma of a ten-years-
old ShihTzu female dog; CIPp were derived from the pri-
mary tumour mass at mammary gland, whereas CIPm from
the metastasis of the primary tumor to the regional lymph
node. Both the primitive tumour and its metastasis cell lines
were first isolated and established by Uyama et al. (2006)
[74] showing that both the cells resulted negative for PR and
ER receptors and positive for HER2 protein. Cultured CIPp
and CIPm cells were maintained in RPMI 1640 with Gluta-
max medium supplemented with 10% FBS, 5mg/L gentami-
cin sulphate, 6mg/L fungizone (complete medium) and
incubated at 37 °C in a humidified atmosphere of 5% CO2.
Reagents were purchased by Gibco-Life Technologies
(Carlsbad CA, USA). Cells were routinely cultured in T25
tissue culture flasks (T 25-Falcon, Beckton-Dickinson,
Franklin Lakes, NJ, USA). Successive experiments were
conducted in 96-well plates (MTT test), 24-well plates
(RNA extraction), 8-slide chambers (DOX-associated
fluorescence evaluation and immunocytochemistry) and
T25 tissue culture flasks (cell cycle analysis and Multidrug
Resistance Direct Dye Efflux Assay). Doxorubicin chloro-
hydrate (2mg/ml) was supplied by Teva Pharmaceutical
Industries (Petah Tiqwa, Israel).
MTT assay and EC50 determination
Cells (3 × 103/well) were plated into 96-well plates,
allowed to attach for 6 h, and treated with 0 μM (con-
trol), 0.2, 0.6, 0.8, 1, 5, 10, 50, 100 μM DOX for 20 h in a
humidified CO2 incubator. Drug was dissolved in
complete medium. Mitochondrial activity, as index of
cell viability, was evaluated by (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide or MTT test
(Sigma-Aldrich, St. Louis, MO, USA) followingmanufacturer’s instructions. Briefly, samples were incu-
bated with MTT solution (0.5 mg/mL in PBS) for 2 h,
formazan crystals were dissolved in 0.1 mL/well of MTT
Solubilization Solution and absorbance spectrophoto-
metrically measured at 570 nm using the Infinite® F50/
−Robotic Absorbance microplate readers (Tecan Life
Sciences, Männedorf, Switzerland).Doxorubicin-associated fluorescence evaluation
Due to its fluorescence properties and the use of a blue
fluorescent dye Hoechst33342 labelling the nucleus, the
intracellular distribution of DOX could be observed by the
fluorescence microscope [75]. Cells (15 × 103/chamber)
were plated in 8-chamber slides with 500 μl of complete
medium and allowed to attach for 24 h in a humidified
CO2 incubator. Medium from each chamber was removed
and cells treated with 0 μM (control) or EC50(20h) DOX
dose: 12.08 and 9.431 μM for CIPp and CIPm respectively.
After 3 and 48 h of DOX treatment, medium was with-
drawn, and cells were stained for 30min a 37 °C with
Hoechst33342 (Miltenyi Biotec) diluted 1:1000 in
complete medium. Cells were washed twice with DPBS
(Gibco-Life Technologies) then chambers were detached
from slides. [Falcon™, Thermo Fisher Scientific, Waltham,
Massachusetts, USA] Coverslips were mounted with
Fluoroshield (Sigma-Aldrich) and images were obtained
with an Eclipse E600 epifluorescence microscope (Nikon,
Japan) equipped with a digital camera (Nikon, Japan).Cell cycle analysis by flow cytometry
CIPp and CIPm were seeded in T25-flask in complete
medium and, when confluence reached approximately
70%, cells were treated with EC50(20h) DOX dose: 12.08
and 9.431 μM for CIPp and CIPm respectively for 3, 6,
12 and 20 h in a humidified CO2 incubator. Untreated
cells were employed as controls. At each time point cells
were harvested and counted. Aliquots of 1 × 106 cells were
washed twice in 5ml of PBS w/o Ca2+ and Mg2+ (Gibco-
Life Technologies) and fixed overnight in 70% ice-cold
ethanol (1ml) added drop-by-drop with continuous vor-
texing. Then, the cells were washed with 10ml of PBS and
cellular pellet was incubated with 1ml of staining solution
containing 50 μg/ml of PI (Miltenyi Biotec, Bergisch Glad-
bach, Germany) and 100 μg/ml RNaseA/T1 (Thermo Sci-
entific) in PBS for 30min in the dark at room temperature
(RT). Cell distribution in cell cycle phases was analyzed by
MACSQuant® Analyzer10 and Flowlogic software (Miltenyi
Biotec). Cellular events were discriminated from debris
using forward (FSC-A) and side scatter (SSC-A). Doublets
have been excluded for analysis by FSC-area and width
(FSC-A/FSC-W). Dean-Jett-Fox Univariate Model was
used to determine the percentage of the cell population in
different phases of the cell cycle [76].
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for P-gp and BCRP after treatments with Doxorubicin
CIPp and CIPm were seeded in a 24 wells plate (105
cells/well) and exposed to DOX EC50(20h) dose for dif-
ferent time (3, 6, 12, 20 and 48 h).
The total RNA was extracted using the TRI Reagent and
the NucleoSpin RNA II kit. At the end of time and treat-
ment, the cells were lysed using TRI Reagent (1000 μl/well)
and mixed by vortex (30 s), then chloroform (200 μl) was
added to the suspension and mixed well. After incubation
at room temperature (10min), the samples were centri-
fuged at 12000 x g for 10min at + 4 °C and the aqueous
phase was recovered. An equal volume (1.1; v.v) of ethanol
(70%) was added and the resulting solution was applied to
the NucleoSpin RNA Column. The RNA purification was
performed according to the manufacturer’s instructions.
The extracted RNA was quantified using the DeNovix DS-
11 Spectrophotometer (DeNovix – Wilmington, DE, USA),
and an A260/A280 ratio was used to evaluate RNA extrac-
tion quality. Five hundred nanograms of RNA were retro-
transcribed to obtain cDNA in a 20 μL final volume, using
an iScript cDNA synthesis kit. Quantitative PCR was
carried out using a CFX96 thermocycler (Bio-Rad Labora-
tories). A master mix of the following reaction components
was prepared in nuclease-free water to the final concentra-
tions indicated: 0.2 μM forward primer, 0.2 μM reverse
primer, and 1X iTaq Universal SYBR Green Supermix.
Two microliters of cDNA were added to 18 μL of master
mix. All samples were analyzed in duplicate. The amplifica-
tion cycle for the real time PCR reaction is: 3min at 95 °C,
40 cycles at 95 °C for 10 s and 60 °C for 30 s, followed by a
melting step from 55 °C going up to 95 °C at a rate of
0.5 °C/5 s increment/cycle. The specificity of the amplified
PCR products was confirmed by agarose gel electrophor-
esis and melting curve analysis.
Primers sequences of interested genes (BCRP and P-gp)
and reference genes (glyceraldehyde 3-phosphate dehydro-
genase, GAPDH; Ribosomal protein L32, Rpl32; Succinate
dehydrogenase, SDHA) are reported in Table 2.Table 2 Informations on primer sequences used for qRT-PCR analys
Gene Sequence (5′-3′) PCR b
P-gp For GCTTAACACCCGGCTCACAGAC 402
Rev TAAGAAAGCGGCACCAATAGAAT
BCRP For TTAGACTCCAGCACAGCAAATG 189
Rev AACCCACTGACGCAAAGAAC
GAPDH For TGTCCCACCCCCAATGTATC 100
Rev CTCCGATGCCTGCTTCACTACCT
Rpl32 For GGCACCAGTCAGACCGATATG 209
Rev GCACATCAGCACTTCAAG
Sdha For CGCATAAGAGCCAAGAAC 194
Rev CCTTCCGTAATGAGACAACReal-time efficiency for interested genes was prelimin-
arily evaluated by amplification of a standardized
amount of cDNA, starting from 150 ng with subsequent
5 dilutions (75, 15, 3, 0.6 and 0.12 ng) derived from liver
sample (positive control) (qPCR efficiency: BCRP 101%,
P-gp 94.7%, data not shown).
The expression level of the interest gene (GI) was deter-
mined using the 2-ΔΔCt method [78] in which ΔCt = (Ct
interest gene – Ct mean ref. genes) and ΔΔCt =ΔCt DOX group -
ΔCt Control group.
Antibodies validation by Western Blotting
Anti-P-gp (clone C494) and anti-BCRP (clone BXP-21)
antibodies were employed after their validation on ca-
nine tissues by Western Blot. For this purpose, canine
liver (positive control) and muscle (negative control) tis-
sue samples were collected, frozen in liquid nitrogen and
stored at −80 °C until sample processing. Hundred milli-
grams of tissue were homogenized in 1 ml of SDS buffer
(Tris-HCl, 62.5 mM; pH 6.8; SDS, 2%; and glycerol, 20%)
supplemented with a protease inhibitor cocktail (Sigma-
Aldrich). Total protein content was determined by
Peterson’s Modification of Lowry Method using a Pro-
tein Assay Kit (Sigma-Aldrich). Ten and 30 μg of total
proteins were separated on NuPage4–12% bis-Tris Gel
(Thermo Scientific, Waltham, MA, USA) for 1 h at 165
V. The proteins were then electrophoretically transferred
onto a nitrocellulose membrane by a semi-dry system
(Trans Turbo Blot, Bio Rad, Hercules, CA, USA). Non-
specific binding on nitrocellulose membranes was
blocked with ECL Blocking Agent (GE Healthcare Life
Sciences, Little Chalfont, Buckinghamshire, UK) in TBS-
T20 (Tris Buffered Saline-0.1% Tween-20) for 1 h at RT.
After blocking treatment, the membranes were incubated
overnight at 4 °C with the primary antibodies anti-P-gp
(clone C494, GeneTex, Irvine, CA, USA) and anti-BCRP
(clone BXP-21, Merck Millipore, Darmstadt, DE) 1:800 and
1:1000 respectively in Blocking Agent. Anti-Alfa-tubulin
antibody (TU-01, Thermo Scientific) was employed tois
p AN Reference
FJ617477.1 Pawlowski et al., 2013 [30]
DQ222459.1 Present study
NM_001003142 Zannoni et al., 2020 [77]
NM_001252169.1 Zannoni et al., 2020 [77]
XM_535807 Zannoni et al.; 2020 [77]
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After washes, the blot was incubated with an anti-mouse
IgG, HRP-linked Antibody (Cell Signaling Technology,
Danvers, MA, USA), at 1:10000 dilution in TBS-T20, 1 h at
RT and then with an anti-biotin horseradish peroxidase
(HRP)-linked antibody (Cell Signaling Technology), (1:100
dilution, 40min at RT).
Immunoreactive bands were visualized using chemi-
luminescent substrate (Clarity Western ECL Substrate,
Bio Rad), according to the manufacturer’s instructions.
The intensity of the luminescent signal was acquired
by Chemidoc Instrument (Bio Rad) and the apparent
molecular weight of the resultant bands was analyzed
by Quantity One Software (Bio-Rad). Western blot ana-
lysis of P-gp and BCRP revealed a single band of expected
molecular weights, ~ 140 kDa and ~ 75 kDa respectively,
in canine liver tissue (30 μg) but not in canine muscle
tissue.
Cell immunocytochemistry
Considering the generational time of the two cell lines
(TCIPp = 23 h and 17 min; TCIPm = 20 h and 29min),
cells (20 × 103 and 15 × 103/chamber per CIPp and CIPm
lines, respectively) were plated in 8-chamber slides (BD
Falcon™ Chamber Cell Culture Slides; Coring Life Sci-
ences, Bedford, MA, USA) with 500 μl of complete
medium (Falcon™, Thermo Fisher Scientific, Waltham,
Massachusetts, USA) and allowed to attach for 24 h in a
humidified CO2 incubator.
The complete culture medium was removed. Fresh
culture medium was added for the controls, instead cul-
ture medium added to DOX at a concentration of 1 μM
was added for treated chambers. Chamber slides were
incubated for 12, 24, 48 h at 37 °C at 5% CO2 to assess
P-gp, BCRP, p53, TERT and Ki67 expression. The control
medium was then removed from chambers, then washed
in. Cells were fixed for 30min in 4% formic aldehyde
buffered at pH 7.2, followed by 3 washings in PBS.
Chamber slides were subjected to endogenous peroxidases
inhibition (H2O2 0.3% in demineralized water for 5min).
Chambers were incubated for 3min with a solution of PBS
at pH 7.2. Each well underwent a 45-min dark pre-
incubation with a serum free blocking solution (Protein
block serum free; Agilent Technologies, Santa Clara, CA,
USA). Chamber slides were then incubated overnight at
4 °C with (1) mouse monoclonal anti-P-gp (clone C494,
GeneTex, Irvine, CA, USA), diluted 1:1500 in 1% bovine
serum albumin (BSA; Sigma-Aldrich) in PBS; with (2)
mouse monoclonal anti-BCRP (clone BXP-21, Merck
Millipore, Darmstadt, DE), diluted 1:800 in 1% BSA in PBS;
with (3) mouse monoclonal anti-Ki67 (clone Mib1, Dako,
Glostrup, DK), diluted 1:600 in 1% BSA in PBS; with (4)
mouse monoclonal anti-p53 (clone Pab 240, BD Pharmin-
gen, San Jose, CA), diluted 1:100 in 1% BSA in PBS; andwith (4) anti-hTERT monoclonal antibody (clone 44F12,
Novocastra, Newcastle upon Tyne, UK), diluted 1:50 in 1%
BSA in PBS. Chamber slides were washed and incubated for
30min with secondary anti-mouse antibody (biotinylated
goat anti-mouse immunoglobulins; Dako, Glostrup, DK) di-
luted 1:200 in 1% BSA in PBS. Avidin-biotin detector com-
plex (Vectastain ABC kit; Vector Laboratories, Burlingame,
CA, USA) was applied for an incubation time of 30min.
Chambers have been removed from the glass base and were
then incubated for approximately 4min with 3, 3’diamino-
benzide tetrahydrochloride (DAB chromogen/substrate kit;
Diagnostic BioSystem, Pleasanton, CA, USA). Sections were
counterstained with Papanicolau’s hematoxylin solution for
45 s. After dehydration in alcohol and clarification in Dia-
phane, slides were mounted. All steps were performed at
room temperature and in the dark, except for the primary
antibody incubation at 4 °C. Each experiment was performed
in triplicate. For each marker negative control were included
and run in parallel. Staining evaluation was performed with
an optical microscope (Eclipse E600; Nikon, Shinjuku,
Japan). The percentage of P-gp, BCRP, p53, TERT and Ki67
immunopositive cells, both for CIPp and CIPm, was calcu-
lated using the ‘Cell Counter Notice’ plug-in of ImageJ (US
National Institutes of Health, Maryland, USA, 2018). For
each marker and replicate of the experiment, a minimum of
1000 cells were evaluated when possible, images taken at op-
tical microscope were analyzed using the NIS-Elements F
image software (Nikon, Shinjuku, Japan). Cell percentages
were averaged over triplicate samples, and the data are
expressed as the mean ± SD.
Multidrug Resistance Direct Dye Efflux Assay
The MDR Direct Dye Efflux Assay kit (Merck, Kenilworth,
NJ, USA) was used to measure P-gp and BCRP activity
following manufacturer’s instructions. CIPp and CIPm
cells, seeded on T25 culture flasks, were detached by tryp-
sinization, counted and 4 aliquots of 1 × 106 cells for each
cell lines were prepared. One aliquot for each cell line was
employed as blank for flow cytometry analysis. Other cell
suspensions were washed in DPBS and loaded with 0.2 μg/
ml of 3,3′-Diethyloxacarbocyanine Iodide DiOC2(3) in
Cold Efflux Buffer (RPMI + 2% BSA) overall named
DiOC2(3) Loading Buffer. Specifically, samples were incu-
bated with 1ml of DiOC2(3) Loading Buffer /1 × 106 cells
for 15min on ice to minimize efflux activity. After the in-
cubation time, cells were washed twice in Cold Efflux Buf-
fer (2.5ml of Cold Efflux Buffer /1 × 106 cells). Cell pellets
were suspended in 3ml of 3 different buffers: 37 °C
Warmed Efflux Buffer (positive control - P); 37 °C Warmed
Efflux Buffer with Vinblastine (V); 4 °C Ice Cold Buffer
(negative control - N). DMSO was added as vehicle con-
trol. Samples in Warmed Efflux Buffer were incubated at
37 °C while samples in Ice Cold Buffer were maintained on
ice for 15min, 1 h, 4 h and 24 h. At the end of each
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Buffer then cell pellets were suspended in 0.5ml of Cold PI
(1:50) Buffer to evaluate cell mortality.
The samples were analysed with the MACSQuant
Analyzer 10 (Miltenyi Biotec Bergisch Gladbach,
Germany) equipped with three lasers (405, 488 and 638
nm). Data analysis was performed using Flowlogic soft-
ware (Miltenyi Biotec, Bergisch Gladbach, Germany).
Cellular events were discriminated from debris using
forward (FSC-A) and side scatter (SSC-A). Doublets
have been excluded from analysis by FSC-area and
weight while dead cells were eliminated from the ana-
lysis basing on PI fluorescence. DiOC2(3) signal (excita-
tion/emission: 482/500) was collected in the B1 channel
(525/50 nm). For each analysis we recorded at least 200,
000 events. Median fluorescence intensity (MFI) of each
peak were considered so differences (Δ) between MFI
values of sample maintained on ice and sample in
warmed buffer (ΔN-P) and between sample in warmed
buffer and sample added with Vinblastine (ΔP-V) were
calculated. For spectral compensation, the following
samples were utilized: cells not stained (Blank), cells
loaded for 15 min on ice with DiOC2(3) Loading Buffer
and cells stained with PI (1:50) in Cold Efflux Buffer. At
the end of the incubation time cells were washed and
suspended in 250 μl of Cold Efflux Buffer. The compen-
sation setting was applied to all analysis.
Statistical analysis
Statistics were calculated with Prism 7 software (Graph-
Pad San Diego, CA, USA). Graphs were created by the
same software.
EC50 determination
EC50(20h) values were calculated using nonlinear regres-
sion curve as previously described [79]. Each treatment
was analysed in quadruplicate, and the experiment was
repeated three times.
Cell cycle analysis
Data statistics were performed with Student’s t test com-
paring the percentage of cells in every phase of cell cycle
(subG0/G1, G0/G1, S, G2/M) in treated vs control cells
at the same time points (3, 6, 12 and 20 h). p < 0.05 was
considered significant.
Gene expression
Data statistics were performed with Student’s t test com-
paring treated vs control at the same time points (3, 6,
12, 20 and 48 h). p < 0.05 was considered significant.
Cell immunocytochemistry
Data statistics were performed with the two-tail Fisher
exact test comparing the percentage of positive cellsbetween controls and DOX treated at each time point
(12, 24, 48 h). p < 0.05 was considered significant.
Multidrug Resistance Direct Dye Efflux Assay
Data statistics were performed by Student’s t test on median
fluorescence intensity (MFI) values comparing the two cell
lines in the same condition (amount of fluorescent dye
effluxed and reduction of dye effluxed in presence of
Vinblastine at 15min and 1, 4, 24 h). p < 0.05 was considered
significant.Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12917-020-02709-5.
Additional file 1. Cell cycle distribution in CIPp. Grouped histograms
graph for CIPp treated with DOX EC50(20h) for 3, 6, 12 and 20 h in
comparison with the relative CTRs. Cell percentages were averaged over
triplicate samples, and the data are expressed as the mean ± SD. Paired
Student’s t-test (parametric data), asterisk indicates a significant difference
(p < 0.05) between controls and treated cells. Sub G0/G1 blue, G0/G1 red,
S yellow, G2/M green.
Additional file 2. Cell cycle distribution in CIPm. Grouped histograms graph
for CIPm treated with DOX EC50(20h) for 3, 6, 12 and 20 h in comparison with
the relative CTRs. Cell percentages were averaged over triplicate samples, and
the data are expressed as the mean ± SD. Paired Student’s t-test (parametric
data), asterisk indicates a significant difference (p< 0.05) between controls and
treated cells. Sub G0/G1 blue, G0/G1 red, S yellow, G2/M green.
Additional file 3. Western Blot for BCRP and P-gp. Canine liver was used
as the positive control and canine skeletal muscle as negative control. The
α-tubulin was used as a housekeeping protein. (A) Western Blot for BCRP
detected a single molecular weight specific band of approximately 75 kDa.
(B) Western Blot for P-gp detected a single molecular weight specific band
of approximately 140 kDa. Lane 1 = 10 μg of liver tissue Lane 2 = 30 μg of
liver tissue Lane 3 = 10 μg of skeletal muscle tissue Lane 4 = 30 μg of skeletal
muscle tissue MWM=Molecular Weight Marker expressed in kDa.
Additional file 4. Immunocytochemistry (ICC) results and statistical
comparisons. P-gp, BCRP, p53, TERT expression and the Ki67 proliferation
index were evaluated in CIPp and CIPm by ICC at 12, 24, 48 h of treat-
ment with the EC50(20h) dose of DOX and compared to the correspond-
ing control cultures.
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